Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - naproxen sodium, quantity: 275 mg - capsule, soft - excipient ingredients: propylene glycol; partially dehydrated liquid sorbitol; povidone; gelatin; glycerol; macrogol 600; brilliant blue fcf; lactic acid; purified water; titanium dioxide; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - provides temporary relief of pain and/or inflammation associated with muscular aches and pains, sprains and strains, backache, osteoarthritis, rheumatic pain, arthritis, headache, period pain, dental pain and cold & flu. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - colecalciferol, quantity: 1000 iu - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; glycerol; hyprolose; purified talc; hydrogenated vegetable oil; butylated hydroxyanisole; butylated hydroxytoluene - aids/assists teeth development ; maintain/support healthy teeth ; maintain/support teeth strength ; maintain/support bone health ; aids/assists healthy bone development/growth/building ; maintain/support bone mass/density/integrity ; maintain/support bone strength ; help maintain/support bone mineralisation ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life ; maintain/support healthy immune system function ; aid/assist muscle development ; maintain/support muscle health ; maintain/support muscle function ; maintain/support absorption of dietary (state vitamin/mineral/nutrient) ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient)

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - colecalciferol, quantity: 1000 iu; calcium carbonate, quantity: 1.4985 g (equivalent: calcium, qty 600 mg) - tablet, film coated - excipient ingredients: maize starch; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; hypromellose; titanium dioxide; macrogol 6000; ethylcellulose; purified talc; iron oxide red; hydrogenated vegetable oil; butylated hydroxyanisole; butylated hydroxytoluene - maintain/support general health and wellbeing ; aids/assists teeth development ; maintain/support healthy teeth ; maintain/support teeth strength ; maintain/support bone health ; aids/assists healthy bone development/growth/building ; maintain/support bone mass/density/integrity ; maintain/support bone strength ; help maintain/support bone mineralisation ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life ; maintain/support healthy immune system function ; aid/assist muscle development ; maintain/support muscle health ; maintain/support muscle function ; maintain/support muscle strength ; maintain/support absorption of dietary (state vitamin/mineral/nutrient) ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient)

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - calcium carbonate, quantity: 1.4985 g (equivalent: calcium, qty 600 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; maize starch; microcrystalline cellulose; magnesium stearate; hypromellose; titanium dioxide; macrogol 6000; purified talc - maintain/support healthy teeth ; maintain/support teeth strength ; helps enhance/promote bone health ; maintain/support bone health ; helps enhance/promote bone strength ; maintain/support bone strength ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; maintain/support muscle strength ; maintain/support (state vitamin/mineral/nutrient) levels in the body

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - vaccinium oxycoccus, quantity: 400 mg (equivalent: vaccinium oxycoccus, qty 10 g) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; crospovidone; colloidal anhydrous silica; magnesium stearate - helps reduce occurrence of medically diagnosed cystitis ; helps decrease/reduce/relieve burning sensation/irritation upon urination associated with medically diagnosed cystitis ; helps decrease/reduce/relieve symptoms of medically diagnosed cystitis ; maintain/support urinary tract health

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - d-alpha-tocopheryl acid succinate, quantity: 198.002 mg (equivalent: d-alpha-tocopherol, qty 200 iu); zinc oxide, quantity: 50.811 mg (equivalent: zinc, qty 40 mg); ascorbic acid, quantity: 250 mg; cupric oxide, quantity: 1.29 mg (equivalent: copper, qty 1 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; calcium hydrogen phosphate; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; ethylcellulose; purified talc; iron oxide yellow; propylene glycol - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support healthy eye function ; maintain/support eye health ; helps maintain/support eye macula health ; helps maintain/support eye retina health ; maintain/support healthy eyesight/vision

Australia - English - Department of Health (Therapeutic Goods Administration)

neo health (otc) pty ltd - thiamine hydrochloride, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; colloidal anhydrous silica; magnesium stearate; purified talc - enhance/promote energy levels ; maintain/support energy levels ; helps convert (state food) into energy ; maintain/support energy production ; maintain/support general health and wellbeing ; maintain/support heart health ; aid/assist/helps glucose/sugar/carbohydrate metabolism ; enhance/improve/promote/increase (state vitamin/mineral/nutrient) levels in the body ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; maintain/support (state vitamin/mineral) within normal range ; help maintain/support emotional wellbeing ; aid/assist/helps synthesis of neurotransmitters ; maintain/support nervous system health ; maintain/support nervous system function

Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - adalimumab, quantity: 40 mg - injection, solution - excipient ingredients: acetic acid; polysorbate 80; sodium acetate trihydrate; glycine; water for injections - rheumatoid arthritis,yuflyma is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. yuflyma can be used alone or in combination with methotrexate.,juvenile idiopathic arthritis,polyarticular juvenile idiopathic arthritis,yuflyma in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to one or more disease modifying anti-rheumatic drugs (dmards). yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.,enthesitis-related arthritis,yuflyma is indicated for the treatment of enthesitis-related arthritis in children, who have had an inadequate response to, or who are intolerant to, conventional therapy.,psoriatic arthritis,yuflyma is indicated for the treatment of signs and symptoms, as well as inhibiting the progression of structural damage, of moderate to severely active psoriatic arthritis in adult patients where response to previous dmards has been inadequate.,ankylosing spondylitis,yuflyma is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. crohn?s disease in adults and children (6 years and older),yuflyma is indicated for the treatment of moderate to severe crohn?s disease, to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients;,? who have had an inadequate response to conventional therapies or,,? who have lost response to or are intolerant to infliximab,ulcerative colitis,yuflyma is indicated for the treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies. patients should show a clinical response within 8 weeks of treatment to continue treatment beyond that time. (see 5.1 pharmacodynamic properties - clinical trials).,psoriasis in adults and children,yuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.,yuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.,hidradenitis suppurativa in adults and adolescents (from 12 years of age),yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.,uveitis,yuflyma is indicated for the treatment of non-infectious intermediate, posterior and pan-uveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - adalimumab, quantity: 40 mg - injection, solution - excipient ingredients: acetic acid; polysorbate 80; sodium acetate trihydrate; glycine; water for injections - rheumatoid arthritis,yuflyma is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. yuflyma can be used alone or in combination with methotrexate.,juvenile idiopathic arthritis,polyarticular juvenile idiopathic arthritis,yuflyma in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to one or more disease modifying anti-rheumatic drugs (dmards). yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.,enthesitis-related arthritis,yuflyma is indicated for the treatment of enthesitis-related arthritis in children, who have had an inadequate response to, or who are intolerant to, conventional therapy.,psoriatic arthritis,yuflyma is indicated for the treatment of signs and symptoms, as well as inhibiting the progression of structural damage, of moderate to severely active psoriatic arthritis in adult patients where response to previous dmards has been inadequate.,ankylosing spondylitis,yuflyma is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. crohn?s disease in adults and children (6 years and older),yuflyma is indicated for the treatment of moderate to severe crohn?s disease, to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients;,? who have had an inadequate response to conventional therapies or,,? who have lost response to or are intolerant to infliximab,ulcerative colitis,yuflyma is indicated for the treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies. patients should show a clinical response within 8 weeks of treatment to continue treatment beyond that time. (see 5.1 pharmacodynamic properties - clinical trials).,psoriasis in adults and children,yuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.,yuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.,hidradenitis suppurativa in adults and adolescents (from 12 years of age),yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.,uveitis,yuflyma is indicated for the treatment of non-infectious intermediate, posterior and pan-uveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - adalimumab, quantity: 40 mg - injection, solution - excipient ingredients: acetic acid; sodium acetate trihydrate; glycine; polysorbate 80; water for injections - rheumatoid arthritis,yuflyma is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. yuflyma can be used alone or in combination with methotrexate.,juvenile idiopathic arthritis,polyarticular juvenile idiopathic arthritis,yuflyma in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to one or more disease modifying anti-rheumatic drugs (dmards). yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.,enthesitis-related arthritis,yuflyma is indicated for the treatment of enthesitis-related arthritis in children, who have had an inadequate response to, or who are intolerant to, conventional therapy.,psoriatic arthritis,yuflyma is indicated for the treatment of signs and symptoms, as well as inhibiting the progression of structural damage, of moderate to severely active psoriatic arthritis in adult patients where response to previous dmards has been inadequate.,ankylosing spondylitis,yuflyma is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. crohn?s disease in adults and children (6 years and older),yuflyma is indicated for the treatment of moderate to severe crohn?s disease, to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients;,? who have had an inadequate response to conventional therapies or,,? who have lost response to or are intolerant to infliximab,ulcerative colitis,yuflyma is indicated for the treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies. patients should show a clinical response within 8 weeks of treatment to continue treatment beyond that time. (see 5.1 pharmacodynamic properties - clinical trials).,psoriasis in adults and children,yuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.,yuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.,hidradenitis suppurativa in adults and adolescents (from 12 years of age),yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.,uveitis,yuflyma is indicated for the treatment of non-infectious intermediate, posterior and pan-uveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate.